Código QR (código de barras bidimensional)

A Real‐World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma in the United States

ABSTRACT Background Tafasitamab, a CD19‐targeting immunotherapy, is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplant. This real‐world study describes patient char...

Fuld beskrivelse

Na minha lista:
Principais autores: Kim Saverno, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Parisa Asgarisabet, Narendranath Epperla
Format: Artigo
Sprog:Inglês
Udgivet: Wiley 2026-04-01
Serier:eJHaem
Fag:
CD19
DLBCL
immunotherapy
real‐world
tafasitamab
Online adgang:https://doi.org/10.1002/jha2.70256
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker